Brought to you by:
Aortobifemoral grafting in the endovascular era: An exploration of the open procedure and its merits among ‘good-risk’ patients today
Aortobifemoral grafting for aortoiliac occlusive disease (AIOD) probably remains “very safe” in the era of endovascular repair, according to the senior author behind a new paper exploring optimal approaches to the often burdensome condition. The research team, led by Jonathan…
WARRIORS randomized trial aims to examine early EVAR in women
This month a multinational collaboration of researchers received endorsement from the Global Cardiovascular Research Funders Forum (GCRFF) Multinational Clinical Trials Initiative for the WARRIORS (Women’s abdominal aortic aneurysm research: repair immediately or routine surveillance) trial. The trial aims to answer…
Treating PAD: ‘Run, don’t walk, to sign up for this incredible course’
No matter if you’re a surgeon with a few years—or a few decades—of experience, faculty members of a new, upcoming Society for Vascular Surgery course say you’re sure to learn valuable skills and strategies to help in treating patients with…
PAD: Endovascular revascularization ‘superior or not significantly different’ in terms of outcomes versus open repair
A real-world analysis of peripheral arterial disease (PAD) patients in Canada indicated open revascularization may not offer a long-term benefit over endovascular intervention. In a population-based retrospective cohort study, researchers from the University of Toronto in Toronto, Ontario, found that…
Black patients wait more than twice as long as White patients for rAAA repair, VQI analysis finds
Black patients saw significantly delayed care for ruptured abdominal aortic aneurysms (rAAAs), with a Vascular Quality Initiative (VQI) analysis showing a median time from hospital admission to intervention of 168 vs. 78 minutes compared to White patients. The finding is part…
TCAR: First patient enrolled in ROADSTER 3 post-approval study
Silk Road Medical has announced enrollment of the first patient in ROADSTER 3, which the company claims is the the first prospective, multicenter, single-arm study to assess real-world treatment of standard surgical risk patients with carotid artery disease using transcarotid…
The top 10 most popular Vascular Specialist stories of August 2022
The top 10 most-read stories on the Vascular Specialist website in August included a look at the state of diversity, equity and inclusion (DEI) in vascular surgery, the confessions of dual-trained vascular- and trauma-trained surgeon, and the digital edition of…
Trial supports full-dose anticoagulation to prevent blood clots in COVID-19 patients
Treatment of critically ill COVID-19 patients with full-dose anticoagulation lowers the risk of venous and arterial clotting complications by 44% compared with the standard dose, according to late breaking research presented in a Hot Line session at ESC Congress 2022 (Aug. 26–29) in Barcelona, Spain.…
SVS meets AMA membership requirement, retains House of Delegates seat
The Society for Vascular Surgery (SVS) has exceeded the necessary compliance threshold required to retain its seat in the American Medical Association (AMA) House of Delegates, the Society has announced. Members were informed that the SVS had received an official…
Clinical outcomes of the ClotTriever system in DVT set to be evaluated in RCT
Inari Medical has announced planned enrollment of the DEFIANCE randomized controlled trial (RCT), which is designed to compare the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only. The trial will enroll 300 patients…